Key Takeaways
- • Congresswoman Pramila Jayapal and Senator Edward J. Markey reintroduced the Health Over Wealth Act on July 23, 2026, targeting private equity ownership across healthcare entities including hospitals, nursing homes, and behavioral health facilities.
- • The legislation mandates enhanced transparency requirements for private equity firms and for-profit companies owning healthcare assets, with a new provision extending scrutiny to PE-backed medical equipment suppliers such as wheelchair manufacturers.
- • The bill establishes safeguards designed to protect workers and patients while addressing healthcare quality, access, and safety concerns; creates accountability mechanisms for corporate consolidation; and closes tax loopholes benefiting real estate investment trusts profiting from healthcare property ownership.
- • The reintroduction addresses documented operational failures in PE-owned healthcare infrastructure, citing specific cases such as dangerously long wheelchair repair wait times for Massachusetts residents caused by private equity-owned suppliers.
- • Legislators frame the legislation as a response to aggressive PE acquisition of healthcare entities, which they characterize as driving worse health outcomes, reduced transparency, and elevated patient costs.
Summary
Congresswoman Pramila Jayapal (D-Washington) and Senator Edward J. Markey (D-Massachusetts) reintroduced the Health Over Wealth Act on July 23, 2026, positioning the bill as a comprehensive regulatory response to private equity consolidation in the U.S. healthcare system. The legislation targets private equity firms and for-profit entities that own hospitals, nursing homes, mental health facilities, and healthcare-related suppliers, establishing mandatory transparency requirements and operational safeguards intended to prioritize patient outcomes over financial returns.
The updated bill introduces a notable expansion of regulatory scope by subjecting private equity-owned medical equipment suppliers—specifically wheelchair manufacturers and distributors—to the same transparency requirements as larger healthcare facilities. This provision directly addresses operational failures in PE-owned supply chains; Jayapal and Markey cited extended wheelchair repair wait times affecting Massachusetts residents as concrete evidence of how private equity cost-optimization strategies can degrade patient care and access to medical equipment.
Beyond transparency mandates, the legislation creates accountability mechanisms designed to constrain corporate cost-cutting practices within healthcare settings and closes tax structures that allow real estate investment trusts to generate profits from healthcare property ownership without direct operational accountability. Jayapal stated the bill aims to "crack down on private equity ownership in healthcare, increase transparency, close loopholes, and ensure that we are putting patients over corporate profits," framing PE consolidation as fundamentally misaligned with healthcare delivery objectives. Senator Markey emphasized that "corporate greed is running rampant in every industry, but it is especially dangerous in healthcare," suggesting the legislation represents a broader regulatory posture toward PE activity in essential services.
The reintroduction signals sustained legislative effort to counter what sponsors characterize as decades of aggressive PE acquisition activity in healthcare, which they argue has produced demonstrable deterioration in health outcomes, reduced operational transparency, and elevated costs for patients. The bill's expanded scope—now encompassing medical equipment suppliers—indicates congressional recognition that PE consolidation effects extend throughout healthcare supply chains, not merely at the facility level.
The updated bill introduces a notable expansion of regulatory scope by subjecting private equity-owned medical equipment suppliers—specifically wheelchair manufacturers and distributors—to the same transparency requirements as larger healthcare facilities. This provision directly addresses operational failures in PE-owned supply chains; Jayapal and Markey cited extended wheelchair repair wait times affecting Massachusetts residents as concrete evidence of how private equity cost-optimization strategies can degrade patient care and access to medical equipment.
Beyond transparency mandates, the legislation creates accountability mechanisms designed to constrain corporate cost-cutting practices within healthcare settings and closes tax structures that allow real estate investment trusts to generate profits from healthcare property ownership without direct operational accountability. Jayapal stated the bill aims to "crack down on private equity ownership in healthcare, increase transparency, close loopholes, and ensure that we are putting patients over corporate profits," framing PE consolidation as fundamentally misaligned with healthcare delivery objectives. Senator Markey emphasized that "corporate greed is running rampant in every industry, but it is especially dangerous in healthcare," suggesting the legislation represents a broader regulatory posture toward PE activity in essential services.
The reintroduction signals sustained legislative effort to counter what sponsors characterize as decades of aggressive PE acquisition activity in healthcare, which they argue has produced demonstrable deterioration in health outcomes, reduced operational transparency, and elevated costs for patients. The bill's expanded scope—now encompassing medical equipment suppliers—indicates congressional recognition that PE consolidation effects extend throughout healthcare supply chains, not merely at the facility level.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.